CAELYX PEGYLATED LIPOSOMAL 2 mg/ml, solution à diluer pour perfusion

( ARTG ) For the treatment of AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm) and extensive mucocutaneous or visceral disease. Caelyx may be used for first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 21 September 2001: For the treatment of: (1) Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. As first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 29 February 2008: CAELYX, as monotherapy, is indicated for the treatment of metastatic breast cancer. CAELYX is also indicated for the treatment of: Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. CAELYX may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). Caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.